Study Links Blood Pressure Drugs ARBs to Cancer
Study Links Blood Pressure Drugs ARBs to Cancer

Blood pressure drugs named angiotensin-receptor blockers have been found to be associated with a higher risk of cancer, an evaluation stated.

It was concluded by analyzing the data of more than 60,000 cases that the patients who were prescribed these drugs had 1.2% more risk of developing cancer as compared to others. The analysis was conducted by Ilke Sipahi and colleagues from Case Western Reserve University School of Medicine in Cleveland as they observed all available public data on the matter.

For knowing the exact role of these drugs in encouraging caner growth, more in-depth studies are needed. The finding is “disturbing and provocative”, said Cardiologist Steven Nissen, of U. S. News's Health Advice Experts.

The findings, published online in the Lancet Oncology, recommends the doctors to be more careful while prescribing angiotensin-receptor blockers (ARBs).

The drug, commonly used in the treatment of high blood pressure, heart failure, and kidney damage due to diabetes, is also associated with a modest increase in the risk of developing cancer, it said.

These drugs function by obstructing receptors for angiotensin II, which is a hormone that is responsible for increasing blood pressure.

Prior to the finding, ARBs were not associated to any other major side effects but the recent study claims that it is associated with a very high risk of deadly cancers.

Latest News

AMD announces ‘Seattle’ microprocessor for server systems
First baby born using 'safer' IVF method
GM recalling 193,652 SUVs from model years 2006 and 2007
Microsoft Office will take time to become available on tablets
Ofsted-style ratings for hospitals
Google to reveal some details about its high-flying balloons
Strong competition between Microsoft and Sony is good for industry: EA
Alcohol-related disease patients deserve better care
U.S. Navy ditches ALL CAPS message format
Nokia to unveil 41MP camera-equipped Lumia EOS smartphone next month
From 2016, Britain to regulate e-cigarettes as medicine
Sprint testing LTE cell sites in San Francisco